Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benef

Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sa

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the pric

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newe

Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raise

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbust

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and ra

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a

Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expec

US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe&#39

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst con

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage imm

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it wil

Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stoc

Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raise

Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials,

Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib deve

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Updat

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s

GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in disc

Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoin

Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disease failed to ‌meet

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irrev

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 milli

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated tran

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data re

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and m

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the pric

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst conse

Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raise

Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperfor

Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raise

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several